Survodutide
Dual GLP-1 and glucagon receptor agonist in Phase 3 trials for obesity and NASH. Adds metabolic rate elevation through glucagon receptor engagement beyond pure GLP-1 activity.
0 anonymous reports
Also known as:
bi-456906glp-1 glucagon survodutide
browse topics:
community guides:
No reports found.
Community Q&A
- What is survodutide and how does it work?
- Community accounts describe survodutide as a next-generation weight-loss compound combining GLP-1 appetite suppression with glucagon-mediated energy expenditure elevation. The glucagon component is consistently described in accounts as producing a meaningfully higher metabolic rate than pure GLP-1 agents — early adopters describe feeling warmer and more energetic on survodutide compared to semaglutide at equivalent appetite suppression levels.
- How does survodutide compare to tirzepatide?
- Community accounts describe different secondary targets: tirzepatide adds GIP (enhancing insulin secretion and fat metabolism), survodutide adds glucagon (increasing energy expenditure). Both are described as superior to pure GLP-1 agents for weight loss. Head-to-head accounts are rare given survodutide's development status. The community interest in survodutide centres on its NASH indication — accounts from users with metabolic liver disease describe it as the most relevant emerging compound for their situation.